Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, previously announced that on February 16, 2023, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("NASDAQ") indicating that the Company was not in compliance with NASDAQ Listing Rule 5250(c)(1) for continued listing (the "Rule") as a result of not having timely filed its annual report on Form 20-F for the year ended September 30, 2022.

On April 19, 2023, the Company filed the Form 20-F, and on April 20, 2023, the Company received a second letter from NASDAQ stating that based on the April 19, 2023 filing of the Company's Form 20-F, NASDAQ has determined that the Company complies with the Rule. Accordingly, NASDAQ informed the Company that it now considers this matter closed.